340B Final Rule Keeps Orphan Drug Exclusion Narrow, Counter To Manufacturers’ Request

HRSA’s final rule on the exclusion of orphan drugs from 340B discounts says the exclusion applies only to the FDA-designated orphan indication, not all uses of a drug with a rare-disease designation.